Dr. Freedland on next steps with cabazitaxel in prostate cancer

Video

Stephen J. Freedland, MD, shares his thoughts on the next steps for cabazitaxel (Jevtana) in the prostate cancer paradigm. Freedland is director of the Center for Integrated Research in Cancer and Lifestyle, co-director of the Cancer Genetics and Prevention Program and associate director for faculty development at the Cancer Institute. He is a faculty physician in the Division of Urology at the Cedars-Sinai Surgery Department.

Freedland is a speaker and consultant for Jevtana developer Sanofi, as well as several other pharmaceutical companies.

Related Videos
Jill M. Hamilton-Reeves, PhD, RD, CSO, answers a question during a Zoom video interview
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Man talking with doctor | © DragonImages - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
blur image background of corridor in hospital or clinic image | Image Credit: © whyframeshot - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.